Simultaneous treatment of ovarian cancer cells with Ac2‐26 and ANXA114‐26 found that ANXA114‐26 reversed the Ac2‐26‐mediated increase in cell viability and drug resistance by competitively binding FPR to Ac2‐26. Here, FPR1 is linked to ovarian cancer.